• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Dec 2, 2020
Product Development

Ovid to focus on rare epilepsy program after Phase III failure for gaboxadol in Angelman syndrome

Ovid is shifting its focus to its other late-stage program, soticlestat, after gaboxadol failed in the Phase III NEPTUNE study to treat Angelman syndrome. Ovid Therapeutics Inc. (NASDAQ:OVID) fell
Read More
BioCentury | Jul 20, 2018
Company News

Takeda, Ovid expand TAK-935 collaboration with three new trials

Read More
BioCentury | Apr 5, 2018
Emerging Company Profile

Stoking protein production

How Stoke is attacking autosomal-dominant disorders with ASOs
Read More
BioCentury | Jan 5, 2018
Clinical News

Ovid reports Phase I data for CYP46A1 inhibitor OV935

Read More
BioCentury | May 6, 2017
Financial News

Ovid dips in first trading day

Read More
BioCentury | May 4, 2017
Financial News

Ovid prices $75M IPO

Read More
Items per page:
1 - 6 of 6
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa